Cardiovascular disease is a leading cause of death in patients with lupus, a systemic autoimmune disease. In a new study in Arthritis & Rheumatology—a journal published by Wiley on behalf of the American College of Rheumatology—imaging tests revealed signs of cardiac impairment in patients newly diagnosed with lupus, even before any symptoms of chest discomfort.
Treatment Goal in Lupus: Low Disease Activity
Corticosteroids Affect Lupus Patients’ Emotional Health, Daily Activities, Study Says
Skin’s Immune ‘Alarm’ May Explain Light-Induced Rashes in Lupus Patients
Lilly to progress Olumiant into Phase 3 for lupus
The Lancet has published full results of a Phase II trial showing the benefit of Lilly’s JAK inhibitor Olumiant in the treatment of global systemic lupus erythematosus (SLE).
According to the data, a statistically significant proportion of patients treated with 4mg of Olumiant (baricitinib) achieved resolution of their SLE-related arthritis or rash compared to placebo at week 24, thus meeting the primary endpoint of the trial.
Scientific and Technology Breakthroughs Show Promise for Lupus and Other Immunologic Diseases
The Lupus Research Alliance is pleased and very encouraged to share a promising scientific breakthrough reported in the New York Times with real potential to revolutionize lupus treatment. Just reported in the prestigious journal Nature, scientists in Dr. Alexander Marson's lab at the University of California, San Francisco have developed an innovative way to engineer genes of the body's immune system to treat immunologic diseases like lupus, rheumatoid arthritis, cancer and HIV.
Levels of Specific Antibodies Linked to Clinical Characteristics of Lupus, Study Reports
Levels of certain antibodies are significantly associated with particular clinical characteristics of systemic lupus erythematosus (SLE), and could be used to assess disease activity in patients, a study finds.
The study, “Antibodies to extractable nuclear antigens (ENAS) in systemic lupus erythematosus patients: correlations with clinical manifestations and disease activity,” was published in the journal Reumatismo.
French Lupus Vaccine Ready to Move Into Phase III
Neovacs, a French biotech, obtained positive Phase IIb results showing its lupus vaccine could be effective in treating this severe autoimmune disease.
Its lupus vaccine works by stimulating the patient’s immune system to produce antibodies against a protein called IFNα that regulates the immune system and is involved in the disease.